News

Breast Cancer Network Australia (BCNA) has welcomed today's decision to recommend a new targeted treatment for metastatic breast cancer for PBS ...
During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor ...
A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...
The UK National Institute for Health and Care Excellence has recommended a targeted twice daily drug treatment that could help around 3000 women a year with advanced breast cancer in England and Wales ...
AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for advanced breast ...
The National Institute for Health and Care Excellence (NICE) has approved the use of the tablet capivasertib, in combination with fulvestrant, for patients with hormone receptor-positive, ...
Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...
"People with advanced breast cancer would value treatments like capivasertib that can be given when limited options exist and ...
Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has approved a “game-changing” twice-a-day pill ...
ETHealthworld.com brings latest breast cancer drug news, views and updates from all top sources for the Indian Health industry.